Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The progression of chronic myelogenous leukemia (CML) to blast crisis is supported by self-renewing leukemic stem cells. In normal mouse hematopoietic stem cells, the process of self-renewal involves the beta-catenin-signaling pathway. We investigated whether leukemic stem cells in CML also use the beta-catenin pathway for self-renewal. METHODS: We used fluorescence-activated cell sorting to isolate hematopoietic stem cells, common myeloid progenitors, granulocyte-macrophage progenitors, and megakaryocyte-erythroid progenitors from marrow during several phases of CML and from normal marrow. BCR-ABL, beta-catenin, and LEF-1 transcripts were compared by means of a quantitative reverse-transcriptase-polymerase-chain-reaction assay in normal and CML hematopoietic stem cells and granulocyte-macrophage progenitors. Confocal fluorescence microscopy and a lymphoid enhancer factor/T-cell factor reporter assay were used to detect nuclear beta-catenin in these cells. In vitro replating assays were used to identify self-renewing cells as candidate leukemic stem cells, and the dependence of self-renewal on beta-catenin activation was tested by lentiviral transduction of hematopoietic progenitors with axin, an inhibitor of the beta-catenin pathway. RESULTS: The granulocyte-macrophage progenitor pool from patients with CML in blast crisis and imatinib-resistant CML was expanded, expressed BCR-ABL, and had elevated levels of nuclear beta-catenin as compared with the levels in progenitors from normal marrow. Unlike normal granulocyte-macrophage progenitors, CML granulocyte-macrophage progenitors formed self-renewing, replatable myeloid colonies, and in vitro self-renewal capacity was reduced by enforced expression of axin. CONCLUSIONS: Activation of beta-catenin in CML granulocyte-macrophage progenitors appears to enhance the self-renewal activity and leukemic potential of these cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Both myelodysplastic syndrome (Pang et al., 2013) and acute and chronic myelogenous leukemias begin with nonlethal mutations in the HSC pool, often leading to successful expansion of mutant HSC clones at the expense of normal HSC, and which progress eventually to leukemia (Corces-Zimmerman et al., 2014; Jamieson et al., 2004; Jan et al., 2012)”
From Quiescent Hematopoietic Stem Cells Accumulate DNA Damage during Aging that Is Repaired upon Entry into Cell Cycle (2014) · cites this paper as Jamieson et al., 2004
In the citing paper
“Although CML is considered a HSC-initiated disease, studies indicate that granulocyte-monocyte progenitors isolated from advanced-phase CML patients reacquire self-renewal properties and therefore may also serve as LSC.6”
From Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo (2010) · cites this paper as [6]
In the citing paper
“Although CML is considered a HSC-initiated disease, studies indicate that granulocyte-monocyte progenitors isolated from advanced-phase CML patients reacquire self-renewal properties and therefore may also serve as LSC.6”
From Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo (2010) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stem cells, cancer, and cancer stem cells
Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC
Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B., & Kinzler, K. W. (1997) · Science · doi:10.1126/science.275.5307.1787 · Cited by 3,942
O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M., Cervantes, F., Cornelissen, J. J., Fischer, T., Hochhaus, A., Hughes, T., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022457 · Cited by 3,570
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Self-citationConstitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC −/− Colon Carcinoma
Korinek, V., Barker, N., Morin, P. J., van Wichen, D., de Weger, R., Kinzler, K. W., Vogelstein, B., & Clevers, H. (1997) · Science · doi:10.1126/science.275.5307.1784 · Cited by 2,905
A clonogenic common myeloid progenitor that gives rise to all myeloid lineages
Akashi, K., Traver, D., Miyamoto, T., & Weissman, I. L. (2000) · Nature · doi:10.1038/35004599 · Cited by 2,617
Self-citationA minute chromosome in human chronic granulocytic leukemia
Nowell̀, P. C. (1960) · Science · Cited by 2,269
Wnt proteins are lipid-modified and can act as stem cell growth factors
Willert, K., Brown, J. D., Danenberg, E., Duncan, A. W., Weissman, I. L., Reya, T., Yates, J. R., & Nusse, R. (2003) · Nature · doi:10.1038/nature01611 · Cited by 2,257
Self-citationA role for Wnt signalling in self-renewal of haematopoietic stem cells
Reya, T., Duncan, A. W., Ailles, L., Domen, J., Scherer, D. C., Willert, K., Hintz, L., Nusse, R., & Weissman, I. L. (2003) · Nature · doi:10.1038/nature01593 · Cited by 2,159
Self-citation
Cited by
Items 801–900 of 1,000
Perrotti, D., Silvestri, G., Stramucci, L., Yu, J. E., & Trotta, R. (2016) · Current Drug Targets · doi:10.2174/1389450117666160615074120 · Cited by 24
“Conversely, in CML-BC GMPs, β-catenin activation is not solely dependent on BCR-ABL1 kinase activity [51, 105] but relies on the cooperation of both BCR-ABL1-independent and –dependent mechanisms [51, 115, 116].”
BackgroundInfluentialBono, S., Lulli, M., D’Agostino, V., Gesualdo, F. D., Loffredo, R., Cipolleschi, M. G., Provenzani, A., Rovida, E., & Sbarba, P. D. (2016) · Oncotarget · doi:10.18632/oncotarget.13319 · Cited by 26
“Reduced BCR promoter activity has been found upon myeloid differentiation from hematopoietic SC to common myeloid progenitors [23, 24].”
Valent, P., Bauer, K., Sadovnik, I., Smiljkovic, D., Ivanov, D., Herrmann, H., Filik, Y., Eisenwort, G., Sperr, W. R., & Rabitsch, W. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.20-0147 · Cited by 22
“loid leukemia and in acute lymphoblastic leukemia, NSG-engrafting stem cells are also found in both, the CD34/CD38 and CD34/ CD38 subfraction of leukemic cells.(22,23) By contrast, normal hemato-”
BackgroundLi, Y., Ahmad, R., Kosugi, M., Kawano, T., Avigan, D., Stone, R. M., Kharbanda, S. M., & Kufe, D. W. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.5.12584 · Cited by 22
“dysregulation of β-catenin that occurs in the development of blast phase.(8) The demonstration that MUC1 is expressed at low to undetectable levels in chronic phase CML, but is upregulated in CML blasts,(10) provides further support for involvement of MUC1 in the more aggressive form of this disease.”
Gatekeeper pathways and cellular background in the pathogenesis and therapy of AML
Cammenga, J. (2005) · Leukemia · doi:10.1038/sj.leu.2403894 · Cited by 27
Richardson, R. B. (2011) · International Journal of Radiation Biology · doi:10.3109/09553002.2010.537430 · Cited by 24
“Thorotrast-administered patients irradiated with high-linear-energy-transfer (high-LET) 232Th alpha-radiation exhibit even greater domination by AML, *4/5ths of the leukaemia cases.”
BackgroundInfluentialEmerging Flt3 kinase inhibitors in the treatment of leukaemia
Tickenbrock, L., Müller‐Tidow, C., Berdel, W. E., & Serve, H. L. (2006) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.11.1.153 · Cited by 22
“Thus, although the identified oncogenes as a group are definitely good therapeutic targets, the effects of therapeutic interventions aimed at single proteins are far less predictable than the effects of, for example, imatinib on Bcr-Abl-positive CML in chronic phase.”
BackgroundInfluentialEpithelial Stem Cells of the Prostate and Their Role in Cancer Progression
Lukacs, R. U., Lawson, D. A., Xin, L., Zong, Y., Garraway, I. P., Goldstein, A. S., Memarzadeh, S., & Witte, O. N. (2008) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2008.73.012 · Cited by 25
Redistribution, homing and organ-invasion of neoplastic stem cells in myeloid neoplasms
Valent, P., Sadovnik, I., Eisenwort, G., Herrmann, H., Bauer, K., Mueller, N., Sperr, W. R., Wicklein, D., & Schumacher, U. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.025 · Cited by 22
Understanding and Monitoring Chronic Myeloid Leukemia Blast Crisis: How to Better Manage Patients
Wang, L., Li, L., Chen, R., Huang, X., & Ye, X. (2021) · Cancer Management and Research · doi:10.2147/cmar.s314343 · Cited by 28
Zhao, H., Pomicter, A. D., Eiring, A. M., Franzini, A., Ahmann, J. M., Hwang, J. Y., Senina, A. V., Helton, B., Iyer, S. M., Yan, D., et al. (2021) · Blood · doi:10.1182/blood.2021011802 · Cited by 20
Nanoparticle-mediated metronomic chemotherapy in cancer: A paradigm of precision and persistence
Kirti, A., Simnani, F. Z., Jena, S., Lenka, S. S., Kalalpitiya, C., Naser, S. S., Singh, D., Choudhury, A., Sahu, R. N., Yadav, A., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216990 · Cited by 22
Harb, J. G., Neviani, P., Chyla, B., Ellis, J. J., Ferenchak, G. J., Oaks, J. J., Walker, C. J., Hokland, P., Roy, D.-C., Caligiuri, M. A., et al. (2013) · Leukemia · doi:10.1038/leu.2013.151 · Cited by 23
Human Acute Myelogenous Leukemia Stem Cells Revisited: There's More Than Meets the Eye
Majeti, R., & Weissman, I. L. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.007 · Cited by 25
“For example, during myeloid blast crisis CML, GMP-like cells exhibit features of LSC (Jamieson et al., 2004).”
BackgroundInfluentialThe role of the bone morphogenetic proteins in leukaemic stem cell persistence
Toofan, P., Irvine, D. A., Hopcroft, L. E. M., Copland, M., & Wheadon, H. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140037 · Cited by 22
Etten, R. A. V., Koschmieder, S., Delhommeau, F., Perrotti, D., Holyoake, T. L., Pardanani, A. D., Mesa, R. A., Green, A. R., Ibrahim, A. R., Mughal, T. I., et al. (2011) · Haematologica · doi:10.3324/haematol.2010.035675 · Cited by 23
“It has been reported that BP GMPs act as LSCs and that acquisition of self-renewal is dependent, at least in part, on BCR-ABL1dependent induction of b-catenin expression/activity.(84;85) However, some recent data suggest that BCR-ABL1 activity is actually dispensable for the b-catenin-dependent self-renewal of BP GMPs…”
BackgroundFZD7 regulates BMSCs-mediated protection of CML cells
Liu, N., Zang, S., Liu, Y., Wang, Y., Li, W., Liu, Q., Ji, M., Ma, D., & Ji, C. (2015) · Oncotarget · doi:10.18632/oncotarget.6742 · Cited by 22
“Supplementary Figure S4: Real-time RT-PCR analysis of FZD7 expression in 55 untreated CML patients and 20 healthy controls.”
BackgroundInfluentialDifferences in expression and function of LEF1 isoforms in normal versus leukemic hematopoiesis
Feder, K., Edmaier, K. E., Rawat, V. P. S., Kirsten, N., Metzeler, K. H., Kraus, J. M., Döhner, K., Döhner, H., Kestler, H. A., Feuring‐Buske, M., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0635-1 · Cited by 22
Modeling the human 8p11-myeloproliferative syndrome in immunodeficient mice
Ågerstam, H., Järås, M., Andersson, A., Johnels, P., Hansen, N., Lassen, C., Rissler, M., Gisselsson, D., Olofsson, T., Richter, J., et al. (2010) · Blood · doi:10.1182/blood-2009-05-217182 · Cited by 21
Abbosh, P. H., Li, X., Li, L., Gardner, T. A., Kao, C. H., & Nephew, K. P. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701024 · Cited by 21
Progress in materials for thermal ablation of cancer cells
Xu, Y., Heberlein, W. E., Mahmood, M., Orza, A. I., Karmakar, A., Mustafa, T. A., Biris, A. R., Casciano, D. A., & Biris, A. S. (2012) · Journal of Materials Chemistry · doi:10.1039/c2jm32792a · Cited by 22
Ferrall‐Fairbanks, M. C., Dhawan, A., Johnson, B., Newman, H., Volpe, V. O., Letson, C. T., Ball, M., Hunter, A. M., Balasis, M. E., Kruer, T. L., et al. (2022) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0217 · Cited by 21
Huang, W., Bei, L., & Eklund, E. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.429696 · Cited by 25
“These investigators found an association between increasing catenin activity in the bone marrow and disease progression in human CML (7).”
BackgroundPrick, J. C. M., de Haan, G., Green, A. R., & Kent, D. G. (2014) · Experimental Hematology · doi:10.1016/j.exphem.2014.07.268 · Cited by 23
“This is mirrored in patients with chronic myeloid leukemia, where HSC self-renewal ability is compromised [113] and BCR-ABL is expressed in only a small proportion of primitive cells [114,115].”
BackgroundCherian, J., Nacro, K., Poh, Z. Y., Guo, S., Jeyaraj, D. A., Wong, Y. X., Ho, M., Yang, H., Joy, J. K., Kwek, P. Z., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01712 · Cited by 19
Inoue, A., Kobayashi, C. I., Shinohara, H., Miyamoto, K., Yamauchi, N., Yuda, J., Akao, Y., & Minami, Y. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2519-y · Cited by 20
Roots of imatinib resistance: A question of self-renewal?
Burchert, A. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.06.001 · Cited by 24
Abourbih, S. R., Sircar, K., Tanguay, S., Kassouf, W., Aprikian, A. G., Mansure, J. J., & Brimo, F. (2013) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-11-298 · Cited by 20
“It has been recently shown that the phenotype of CSCs is a reflection of both its cell of origin as well as the oncogenic transforming events [13,14].”
BackgroundChuang, K., Lieu, C. H., Tsai, W.-J., Wu, M. H., Chen, Y. C., Liao, J., Wang, C. C., & Kuo, Y.-H. (2010) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2010007500091 · Cited by 23
“These cells possess self-renewal ability like stem cells and are responsible for relapse even under Imatinib treatment (5-8).”
BackgroundCancer Stem Cells: From Bench to Bedside
Jones, R. J., & Matsui, W. H. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2006.10.010 · Cited by 21
Subramaniam, A., Pattnayak, N. C., & Chakraborty, S. (2016) · Scientific Reports · doi:10.1038/srep32493 · Cited by 20
“CML stem cells are known to reside in the lin( − ) CD34 + CD38 − population and recently it was reported that the progenitor cells acquire stem cell properties which results in the progression of the disease 3 .”
Hu, J., Feng, M. H., Liu, Z., Liu, Y., Huang, Z., Li, H., & Feng, W. (2016) · Tumor Biology · doi:10.1007/s13277-016-5413-3 · Cited by 21
“Studies have shown that blastic transformation in CML is related to overexpression of BCR-ABL and activation of β-catenin in granulocyte macrophage precursors from CML patients [15, 21].”
BackgroundLi, Y., Hu, J., Song, H., & Wu, T. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.09.183 · Cited by 20
Phenotypic characterization of leukemia-initiating stem cells in chronic myelomonocytic leukemia
Eisenwort, G., Sadovnik, I., Keller, A., Ivanov, D., Peter, B., Berger, D., Stefanzl, G., Bauer, K., Slavnitsch, K., Greiner, G., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01227-z · Cited by 20
Jalkanen, S. E., Lahesmaa‐Korpinen, A., Heckman, C. A., Rantanen, V., Porkka, K., Hautaniemi, S., & Mustjoki, S. M. (2012) · Experimental Hematology · doi:10.1016/j.exphem.2012.05.010 · Cited by 19
“Previous studies have shown that CML patients with accelerated-phase disease or blast crisis have increased b-catenin levels in myeloid progenitor cells, which is speculated to enhance the self-renewal activity and leukemic potential of these cells [42].”
BackgroundDNA damage response, redox status and hematopoiesis
Weiss, C. N., & Ito, K. (2013) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2013.08.002 · Cited by 22
“It is well established that DNA damage is central to the development of malignancy, and the role of stem cells in establishing malignancy in the hematopoietic compartment and other tissues, has been widely recognized [25; 26; 27].”
BackgroundBockamp, E., Antunes, C., Maringer, M., Heck, R., Presser, K., Beilke, S., Ohngemach, S., Alt, R., Cross, M., Sprengel, R., et al. (2006) · Blood · doi:10.1182/blood-2005-12-012104 · Cited by 19
“lin c-kit EGFP 38 (24-52) 5 (3-7) 35 (22-47) 10 (5-14)”
Molecular profiling of stem cells
Ma, L., Sun, B., Hood, L., & Tian, Q. (2007) · Clinica Chimica Acta · doi:10.1016/j.cca.2006.12.016 · Cited by 19
Aplastic anemia following exposure to paradichlorobenzene and naphthalene.
Harden, R. A., & Baetjer, A. (1978) · PubMed · Cited by 26
Chimge, N., Chen, M.-H., Nguyen, C., Zhao, Y., Wu, X., García-González, P. A., Ogana, H. A. N., Hurwitz, S., Teo, J.-L., Chen, X., et al. (2023) · Current Molecular Pharmacology · doi:10.2174/1874467217666230906092236 · Cited by 24
Tanizaki, R., Nomura, Y., Miyata, Y., Minami, Y., Abe, A., Hanamura, A., Sawa, M., Murata, M., Kiyoi, H., Matsushita, T., et al. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01440.x · Cited by 18
Insertional Mutagenesis by Replication‐Deficient Retroviral Vectors Encoding the Large T Oncogene
Li, Z., Kustikova, O. S., Kamino, K., NEUMANN, T., Rhein, M., Grassman, E., Fehse, B., & Baum, C. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1392.003 · Cited by 19
CBP/Catenin antagonists: Targeting LSCs’ Achilles heel
Kim, Y., Gang, E., & Kahn, M. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.04.010 · Cited by 19
The Cure of Chronic Myeloid Leukemia: Are We There Yet?
Saikia, T. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0665-2 · Cited by 21
Esmailzadeh, S., & Jiang, X. (2011) · Oncotarget · doi:10.18632/oncotarget.405 · Cited by 20
Bcr interferes with β‐catenin–Tcf1 interaction
Reß, A., & Moelling, K. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.01.034 · Cited by 19
“chronic myelogenous leukemia, CML, which enhance the self-renewal activity and leukemic potential [34,35].”
BackgroundOncoprotein BMI‐1 induces the malignant transformation of HaCaT cells
Wang, Q., Li, W., You, P., Su, J., Zhu, M.-H., Xie, D., Zhu, H., He, Z., Li, J., Ding, X., et al. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21969 · Cited by 19
“…is essentially a disease of stem cells is receiving increasing support, with the discovering of ‘‘cancer stem cells’’ in acute myeloid leukemia [Lapidot et al., 1994], chronic myeloid leukemia [Jamieson et al., 2004], breast cancer [Al-Hajj et al., 2003], and medulloblastoma [Singh et al., 2003].”
BackgroundRole of the bone morphogenic protein pathway in developmental haemopoiesis and leukaemogenesis
Toofan, P., & Wheadon, H. (2016) · Biochemical Society Transactions · doi:10.1042/bst20160104 · Cited by 18
Pathway of peritoneal carcinomatosis maybe hematogenous metastasis rather than peritoneal seeding
Ge, W., Chen, G., & Fan, X. (2017) · Oncotarget · doi:10.18632/oncotarget.14607 · Cited by 18
“Leukemia cancer cells divided and amplified like stem cells [20].”
BackgroundTherapy Resistance and Disease Progression in CML: Mechanistic Links and Therapeutic Strategies
Ng, J. J., & Ong, S. T. (2022) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-022-00679-z · Cited by 18
Sun, C., Luan, S., Zhang, G., Wang, N., Shao, H.-Y., & Luan, C. (2017) · Europe PMC (PubMed Central) · Cited by 24
Gener, P., González‐Callejo, P., Seras‐Franzoso, J., Andrade, F., Rafael, D. F. D. S., Abasolo, I., & Schwartz, S. (2020) · Nanomedicine · doi:10.2217/nnm-2020-0099 · Cited by 18
Aldehyde dehydrogenase 1: A specific cancer stem cell marker for human colorectal carcinoma
ZHOU, F., Mu, Y., Liang, J., Liu, Z., Zhou, D., Ning, W., Li, Y., Ding, D., & ZHANG, J.-F. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3195 · Cited by 17
“It has been established that cancer stem cells (CSCs) have a phenotype that can be defined by their cell of origin [stem cell (SC) or early progenitor cells] and by oncogenic events, which contribute to their transformation (5).”
The Impact of the Cellular Origin in Acute Myeloid Leukemia: Learning From Mouse Models
Fisher, J. N., Kalleda, N., Stavropoulou, V., & Schwaller, J. (2019) · HemaSphere · doi:10.1097/hs9.0000000000000152 · Cited by 23
“It will be important to determine the combination of preleukemic mutations with the highest risk for progressing into de novo AML or inducing MDS/MPN that ultimately progresses to AML.”
BackgroundInfluentialRecent advances in the development of novel anti‐cancer drugs targeting cancer stem/progenitor cells
Mimeault, M., & Batra, S. K. (2008) · Drug Development Research · doi:10.1002/ddr.20273 · Cited by 17
“In fact, arsenic trioxide can induce the anti-proliferative and/or proapoptotic effect on PML-RAR-a1 APL cells including LSCs.”
BackgroundInfluentialSigner, R. A. J., Montecino‐Rodriguez, E., Witte, O. N., & Dorshkind, K. A. (2010) · Blood · doi:10.1182/blood-2010-01-264093 · Cited by 19
CML: a model for targeted therapy
Cilloni, D., & Saglio, G. N. (2009) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2009.04.004 · Cited by 23
Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies
Martelli, A. M., Paganelli, F., Evangelisti, C., Chiarini, F., & McCubrey, J. A. (2022) · Cells · doi:10.3390/cells11111812 · Cited by 17
Wnt regulation of hematopoietic stem cell development and disease
Carpenter, K. A., Thurlow, K. E., Craig, S. E. L., & Grainger, S. J. (2023) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2022.12.001 · Cited by 20
Is cancer a stem cell disease? Theory, evidence and implications
Blacking, T., Wilson-Robles, H. M., & Argyle, D. J. (2007) · Veterinary and Comparative Oncology · doi:10.1111/j.1476-5829.2007.00127.x · Cited by 16
The evolution of cancer modeling: the shadow of stem cells
Vicente‐Dueñas, C., Cobaleda, C., Pérez‐Losada, J., & Sánchez-García, I. (2010) · Disease Models & Mechanisms · doi:10.1242/dmm.002774 · Cited by 15
“However, the BCR-ABL translocation, which is pathognomonic of this disease, does not arise in a granulocyte, but rather in a cell at the top of the hematopoietic differentiation tree (Jamieson et al., 2004).”
BackgroundLund, H. L., Hughesman, C. B., McNeil, K., Clemens, S., Hocken, K., Pettersson, R., Karsan, A., Foster, L. J., & Haynes, C. A. (2015) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-015-9204-2 · Cited by 17
Novel Drug Therapies in Myeloid Leukemia: a Patent Review
Horne, G. A., Kinstrie, R., & Copland, M. (2015) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.15.3 · Cited by 18
Modeling the Role of Wnt Signaling in Human and Drosophila Stem Cells
Kaur, P., Jin, H. J., Lusk, J. B., & Tolwinski, N. S. (2018) · Genes · doi:10.3390/genes9020101 · Cited by 17
“The converse of healthy stem cells are cancer cells, which retain the ability to self-renew but instead of regenerating specific organs, generate abnormal growths which are all hallmarks of Wnt-related cancers [15,16].”
BackgroundPhosphatase and Tensin Homologue: Novel Regulation by Developmental Signaling
Jerde, T. J. (2015) · Journal of Signal Transduction · doi:10.1155/2015/282567 · Cited by 17
Ruxolitinib induces autophagy in chronic myeloid leukemia cells
Bağca, B. G., Özalp, Ö., Kurt, C. Ç., Mutlu, Z., Saydam, G., Gündüz, C., & Avcı, Ç. B. (2015) · Tumor Biology · doi:10.1007/s13277-015-3947-4 · Cited by 17
Evolutionary Dynamics of Chronic Myeloid Leukemia
Dingli, D., Traulsen, A., Lenaerts, T., & Pacheco, J. M. (2010) · Genes & Cancer · doi:10.1177/1947601910371122 · Cited by 20
Of Germ Cells, Trophoblasts, and Cancer Stem Cells
Burleigh, A. (2008) · Integrative Cancer Therapies · doi:10.1177/1534735408326454 · Cited by 17
Stem Cells and Somatic Cells: Reprogramming and Plasticity
Estrov, Z. E. (2009) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2009.s.031 · Cited by 21
Huang, W., Luan, C.-H., Hjort, E. E., Bei, L., Mishra, R., Sakamoto, K. M., Platanias, L. C., & Eklund, E. A. (2016) · Leukemia · doi:10.1038/leu.2016.66 · Cited by 19
Stem-Cell-Based Tumorigenesis in Adult Drosophila
Hou, S. X., & Singh, S. R. (2016) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/bs.ctdb.2016.07.013 · Cited by 18
Ruan, X., Jiang, W.-H., Cheng, P., Huang, L., Li, X., He, Y., Mai, M., & Tan, Z. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.063 · Cited by 16
RetractedNteliopoulos, G., Marley, S. B., & Gordon, M. Y. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07823.x · Cited by 22
“These findings and the fact that Wnt signalling has been demonstrated to be present in primary chronic myeloid (Jamieson et al, 2004), acute myeloid (Simon et al, 2005) and chronic lymphoid (Lu et al, 2004) leukaemia cells shows the importance of precise control of the Wnt pathway in haematopoiesis.”
BackgroundBreast Cancer, a Stem Cell Disease
Pérez‐Losada, J., & González‐Sarmiento, R. (2008) · Current Stem Cell Research & Therapy · doi:10.2174/157488808783489453 · Cited by 18
Shi, Y., Rand, A. J., Crow, J. H., Moore, J. O., & Lagoo, A. S. (2014) · American Journal of Clinical Pathology · doi:10.1309/ajcpwex5yy4phscn · Cited by 16
Chronic Myelogenous Leukemia — Identifying the Hydra's Heads
Clarke, M. F. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048120 · Cited by 16
Viragova, S., Aparicio, L., Palmerini, P., Zhao, J., Salazar, L. E. V., Schurer, A., Dhuri, A., Sahoo, D., Moskaluk, C. A., Rabadán, R., et al. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad062 · Cited by 15
Identification of drug-resistant subpopulations in canine hemangiosarcoma
Khammanivong, A., Gorden, B. H., Frantz, A., Graef, A., & Dickerson, E. B. (2014) · Veterinary and Comparative Oncology · doi:10.1111/vco.12114 · Cited by 14
Karvela, M., Helgason, G. V., & Holyoake, T. L. (2012) · Expert Review of Anticancer Therapy · doi:10.1586/era.12.10 · Cited by 18
Molecular signatures of chronic myeloid leukemia stem cells
Chen, Y., & Li, S. (2013) · Biomarker Research · doi:10.1186/2050-7771-1-21 · Cited by 18
“In CML patients undergoing blast crisis, β-catenin is activated in myeloid progenitors and the activated β-catenin translocates to the nucleus [24].”
BackgroundMultifaceted Mechanisms for Cell Survival and Drug Targeting in Chronic Myelogenous Leukemia
Kuroda, J., Shimura, Y., Yamamoto‐Sugitani, M., Sasaki, N., & Taniwaki, M. (2012) · Current Cancer Drug Targets · doi:10.2174/156800913804486638 · Cited by 15
Chen, Y., Tan, Y.-Y., Yao, M., Lin, H.-C., Tsai, M.-H., Li, Y.-Y., Hsu, Y., Huang, T., Chang, C., Cheng, C., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102888 · Cited by 17
“(I) Histogram showed the percentages of cells in G2/M phase of the cell cycle after BPA exposure for 72 hr *p < 0.05 indicated a significant difference between siCTNNB1 transfection and vehicle. indicated the importance of angiogenesis and angiogenic therapy to B cell NHL (Jiang and Li, 2020).”
BackgroundInfluentialSignaling pathways and their potential therapeutic utility in esophageal squamous cell carcinoma
Kadian, L. K., Arora, M., Prasad, C. P., Pramanik, R., & Chauhan, S. S. (2022) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02763-x · Cited by 18
Yen, R., Grasedieck, S., Wu, A., Lin, H., Su, J., Rothe, K., Nakamoto, H., Forrest, D. L., Eaves, C. J., & Jiang, X. (2022) · Leukemia · doi:10.1038/s41375-022-01680-4 · Cited by 15
“in the CD34CD38 stem cell-enriched population compared to the bulk CD34 population [45, 48].”
BackgroundManagement of Advanced-Phase Chronic Myeloid Leukemia
DeFilipp, Z. M., & Khoury, H. J. (2015) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-015-0249-2 · Cited by 15
Characterization of leukemic cell behaviors in a soft marrow mimetic alginate hydrogel
Vu, T. T. T., Lim, C. S. S., & Lim, M. (2012) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.32765 · Cited by 16
Jiang, J., & Griffin, J. D. (2010) · Genes & Cancer · doi:10.1177/1947601910362446 · Cited by 17
Hu, T., Li, C., Zhang, Y., Wang, L., Peng, L., Cheng, H., Wang, W., Chu, Y., Xu, M., Cheng, T., et al. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.03.007 · Cited by 15
Huang, W., Bei, L., & Eklund, E. A. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.720979 · Cited by 19
The Biology and Pathogenesis of Chronic Myeloid Leukemia
Chereda, B., & Melo, J. V. (2016) · Hematologic malignancies · doi:10.1007/978-3-319-33198-0_2 · Cited by 15
Heterogeneous leukemia stem cells in myeloid blast phase chronic myeloid leukemia
Kinstrie, R., Karamitros, D., Goardon, N., Morrison, H., Hamblin, M., Robinson, L., Clark, R. E., Copland, M., & Vyas, P. (2016) · Blood Advances · doi:10.1182/bloodadvances.2016000810 · Cited by 21
Tan, Z., Peng, A., Xu, J., & Ouyang, M.-W. (2017) · BMC Anesthesiology · doi:10.1186/s12871-017-0423-2 · Cited by 15
“CML is recognized to be a hematopoietic stem cell disorder and CD34 cells serve as a reservoir for disease relapse [8].”
BackgroundKarabay, A. Z., Koç, A., Özkan, T., Hekmatshoar, Y., Güneş, B. A., Sunguroğlu, A., Büyükbingöl, Z., Atalay, A., & Aktan, F. (2018) · Hematology · doi:10.1080/10245332.2018.1488795 · Cited by 15
“nucleus in order to regulate the expression of several genes [26].”
BackgroundLeguay, T., & Mahon, F. (2005) · Encyclopédie médico-chirurgicale. Hématologie · doi:10.1016/j.emch.2005.07.001 · Cited by 34
Luo, L., & Han, Z. (2006) · International Journal of Hematology · doi:10.1532/ijh97.a10503 · Cited by 18
“The research of Jamieson et al [ 12 ] revealed higher levels of CD34 + Lin ‐ cells in bone marrow from patients with CML in the accelerated or blast phase than in normal bone marrow.”
BackgroundInfluentialSignoretto, I., Calzetti, F., Finotti, G., Lonardi, S., Balanzin, C., Bianchetto-Aguilera, F. M., Gasperini, S., Gardiman, E., Castellucci, M., Russignan, A., et al. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01259-w · Cited by 19
“Importantly, we also con fi rmed previous observations [24, 25] on the signi fi cant decrease in cGMP from the BM of CP-CML patients compared with the BM of HDs (Fig.”
Predicting the Response of CML Patients to Tyrosine Kinase Inhibitor Therapy
White, D. L., & Hughes, T. P. (2011) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-011-0087-9 · Cited by 13
“Using pathway analysis, the gene pattern of nonresponders was linked to activation of β-catenin, previously shown to be involved in disease progression [40].”
MethodHuman skin neural crest progenitor cells are susceptible to BRAFV600E-induced transformation
Kumar, S., Dai, J., Li, S., Yang, R., Yu, H., Nathanson, K. L., Liu, S., Zhou, H., Guo, J., & Xu, X. (2013) · Oncogene · doi:10.1038/onc.2012.642 · Cited by 17
Maintaining Low BCR-ABL Signaling Output to Restrict CML Progression and Enable Persistence
Burchert, A. (2014) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-013-0196-8 · Cited by 17
“Prominent examples would be the deletion of the CDKN2A locus (deleting INK4A and ARF) [30, 69, 79], p53 mutations [58], β-Catenin overexpression [28], by conferring”
BackgroundYeung, K. Y., Gooley, T. A., Zhang, A., Raftery, A. E., Radich, J. P., & Oehler, V. G. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts059 · Cited by 17
Metadata
- Authors
- Jamieson, C. H. M., Ailles, L. E., Dylla, S. J., Muijtjens, M., Jones, C., Zehnder, J. L., Gotlib, J., Li, K., Manz, M. G., Keating, A., Sawyers, C. L., & Weissman, I. L.
- Affiliations
- Stanford Medicine (US)
- University of Toronto (CA)
- University of California, Los Angeles (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-08-12
- Volume
- 351
- Issue
- 7
- Pages
- 657-667
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2012962381
- Cited by
- 1,485
- References
- 58
- Citations by year
- 2026: 7 · 2025: 15 · 2024: 19 · 2023: 36 · 2022: 27 · 2021: 33 · 2020: 40 · 2019: 37 · 2018: 40 · 2017: 53 · 2016: 80 · 2015: 74 · 2014: 81 · 2013: 95 · 2012: 114
- FWCI
- 55.80
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (K23HL04409, K23HL004409)
- National Cancer Institute (2PO1CA49605, CA 86017, CA 55209, R01CA086017, P01CA049605)
- National Institute of Allergy and Infectious Diseases (5 T32 AI07290, T32AI007290)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- chronic myeloid leukemia, blast crisis, leukemia stem cells, CFU-GM, β-catenin signaling, BCR-ABL, self-renewal, Axin, imatinib resistance, hematopoietic stem cells, myeloid progenitor cells
- MeSH terms
- Imatinib Mesylate, Adult, Aged, Antineoplastic Agents, Benzamides, Blast Crisis, Colony-Forming Units Assay, Cytoskeletal Proteins, DNA-Binding Proteins, Female, Granulocytes, Hematopoietic Stem Cells, Humans, Macrophages, Male, Middle Aged, Piperazines, Pyrimidines, RNA, Neoplasm, Transcription Factors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Trans-Activators, Fusion Proteins, bcr-abl, Microscopy, Confocal, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, beta Catenin, Lymphoid Enhancer-Binding Factor 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.